Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges
- PMID: 33977438
- DOI: 10.1007/5584_2021_639
Stem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges
Abstract
Lysosomal storage disorders (LSDs) are rare inborn errors of metabolism caused by defects in lysosomal function. These diseases are characterized by accumulation of completely or partially degraded substrates in the lysosomes leading to cellular dysfunction of the affected cells. Currently, enzyme replacement therapies (ERTs), treatments directed at substrate reduction (SRT), and hematopoietic stem cell (HSC) transplantation are the only treatment options for LSDs, and the effects of these treatments depend strongly on the type of LSD and the time of initiation of treatment. However, some of the LSDs still lack a durable and curative treatment. Therefore, a variety of novel treatments for LSD patients has been developed in the past few years. However, despite significant progress, the efficacy of some of these treatments remains limited because these therapies are often initiated after irreversible organ damage has occurred.Here, we provide an overview of the known effects of LSDs on stem cell function, as well as a synopsis of available stem cell-based cell and gene therapies that have been/are being developed for the treatment of LSDs. We discuss the advantages and disadvantages of use of hematopoietic stem cell (HSC), mesenchymal stem cell (MSC), and induced pluripotent stem cell (iPSC)-related (gene) therapies. An overview of current research data indicates that when stem cell and/or gene therapy applications are used in combination with existing therapies such as ERT, SRT, and chaperone therapies, promising results can be achieved, showing that these treatments may result in alleviation of existing symptoms and/or prevention of progression of the disease. All together, these studies offer some insight in LSD stem cell biology and provide a hopeful perspective for the use of stem cells. Further development and improvement of these stem cell (gene) combination therapies may greatly improve the current treatment options and outcomes of patients with a LSD.
Keywords: Gene therapy; Hematopoietic stem cell; Induced pluripotent stem cell; Lysosomal storage disease; Lysosomal storage disorder; Mesenchymal stem cell; Neural stem cell; Stem cell.
© 2021. Springer Nature Switzerland AG.
Similar articles
-
Advances in therapies for neurological lysosomal storage disorders.J Inherit Metab Dis. 2023 Sep;46(5):874-905. doi: 10.1002/jimd.12615. Epub 2023 May 2. J Inherit Metab Dis. 2023. PMID: 37078180 Review.
-
Treatment options for lysosomal storage disorders: developing insights.Expert Opin Pharmacother. 2012 Nov;13(16):2281-99. doi: 10.1517/14656566.2012.729039. Epub 2012 Sep 26. Expert Opin Pharmacother. 2012. PMID: 23009070 Review.
-
Evolving therapies in neuronopathic LSDs: opportunities and challenges.Metab Brain Dis. 2022 Oct;37(7):2245-2256. doi: 10.1007/s11011-022-00939-0. Epub 2022 Apr 20. Metab Brain Dis. 2022. PMID: 35442005 Review.
-
Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.Mol Ther. 2017 May 3;25(5):1155-1162. doi: 10.1016/j.ymthe.2017.03.025. Epub 2017 Apr 4. Mol Ther. 2017. PMID: 28389320 Free PMC article. Review.
-
Role of induced pluripotent stem cells in lysosomal storage diseases.Mol Cell Neurosci. 2020 Oct;108:103540. doi: 10.1016/j.mcn.2020.103540. Epub 2020 Aug 21. Mol Cell Neurosci. 2020. PMID: 32828964 Review.
Cited by
-
A kaleidoscopic view of extracellular vesicles in lysosomal storage disorders.Extracell Vesicles Circ Nucl Acids. 2022 Dec 30;3(4):393-421. doi: 10.20517/evcna.2022.41. eCollection 2022. Extracell Vesicles Circ Nucl Acids. 2022. PMID: 39697359 Free PMC article. Review.
-
Increasing β-hexosaminidase A activity using genetically modified mesenchymal stem cells.Neural Regen Res. 2024 Jan;19(1):212-219. doi: 10.4103/1673-5374.375328. Neural Regen Res. 2024. PMID: 37488869 Free PMC article.
-
Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.Orphanet J Rare Dis. 2022 Oct 21;17(1):383. doi: 10.1186/s13023-022-02543-y. Orphanet J Rare Dis. 2022. PMID: 36271424 Free PMC article.
References
-
- Ahmad I, Hunter RE, Flax JD, Snyder EY, Erickson RP (2007) Neural stem cell implantation extends life in Niemann-Pick C1 mice. J Appl Genet 48(3):269–272 - PubMed
-
- Aldenhoven M, Kurtzberg J (2015) Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions. Cytotherapy 17(6):765–774 - PubMed
-
- Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC et al (2014) Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. Bone Marrow Transplant 49(8):1016–1021 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous